Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-06-09
2008-12-30
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388800, C530S391300, C530S391700, C424S133100, C424S135100, C424S143100, C424S155100, C424S181100, C424S183100, C435S007230, C435S069600, C435S070210, C435S320100, C536S023530
Reexamination Certificate
active
07470775
ABSTRACT:
CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
REFERENCES:
patent: WO 9622384 (1996-07-01), None
Nagata et al. Clinical Cancer Research, 8(7):2345-2355, Jul. 2002.
William E. Paul. Fundamental Immunology, 3rd Edition, pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
Beers Richard
Kreitman Robert
Nagata Satoshi
Numata Yoshito
Onda Masanori
Blanchard David J.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Anti-CD30 stalk and anti-CD30 antibodies suitable for use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD30 stalk and anti-CD30 antibodies suitable for use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD30 stalk and anti-CD30 antibodies suitable for use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036325